Search

Your search keyword '"Bakkum-Gamez, Jamie N"' showing total 448 results
Start Over Author "Bakkum-Gamez, Jamie N" Publication Year Range Last 10 years
448 results on '"Bakkum-Gamez, Jamie N"'

5. Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease

Author

Bartemes, Kathleen R., Gochanour, Benjamin R., Routman, David M., Ma, Daniel J., Doering, Karen A., Burger, Kelli N., Foote, Patrick H., Taylor, William R., Mahoney, Douglas W., Berger, Calise K., Cao, Xiaoming, Then, Sara S., Haller, Travis J., Larish, Alyssa M., Moore, Eric J., Garcia, Joaquin J., Graham, Rondell P., Bakkum-Gamez, Jamie N., Kisiel, John B., and Van Abel, Kathryn M.

Published
2023
Full Text
View/download PDF

7. Detection of endometrial cancer using tampon-based collection and methylated DNA markers

Author

Bakkum-Gamez, Jamie N., Sherman, Mark E., Slettedahl, Seth W., Mahoney, Douglas W., Lemens, Maureen A., Laughlin-Tommaso, Shannon K., Hopkins, Matthew R., VanOosten, Ann, Shridhar, Viji, Staub, Julie K., Cao, Xiaoming, Foote, Patrick H., Clarke, Megan A., Burger, Kelli N., Berger, Calise K., O'Connell, Maria C., Doering, Karen A., Podratz, Karl C., DeStephano, Christopher C., Schoolmeester, J. Kenneth, Kerr, Sarah E., Wentzensen, Nicolas, Taylor, William R., and Kisiel, John B.

Published
2023
Full Text
View/download PDF

8. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Author

Secord, Angeles Alvarez, Burdett, Kirsten Bell, Owzar, Kouros, Tritchler, David, Sibley, Alexander B, Liu, Yingmiao, Starr, Mark D, Brady, J Chris, Lankes, Heather A, Hurwitz, Herbert I, Mannel, Robert S, Tewari, Krishnansu S, O'Malley, David M, Gray, Heidi, Bakkum-Gamez, Jamie N, Fujiwara, Keiichi, Boente, Matthew, Deng, Wei, Burger, Robert A, Birrer, Michael J, and Nixon, Andrew B

Subjects
Clinical Trials and Supportive Activities, Ovarian Cancer, Rare Diseases, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Biomarkers, Tumor, Carboplatin, Carcinoma, Ovarian Epithelial, Double-Blind Method, Female, Humans, Interleukin-6, Middle Aged, Ovarian Neoplasms, Paclitaxel, Survival Rate, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeGOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demonstrated significantly improved progression-free survival (PFS), but no overall survival (OS) benefit with bevacizumab. Blood samples were collected for biomarker analyses.Experimental designPlasma samples were analyzed via multiplex ELISA technology for seven prespecified biomarkers [IL6, Ang-2, osteopontin (OPN), stromal cell-derived factor-1 (SDF-1), VEGF-D, IL6 receptor (IL6R), and GP130]. The predictive value of each biomarker with respect to PFS and OS was assessed using a protein marker by treatment interaction term within the framework of a Cox proportional hazards model. Prognostic markers were identified using Cox models adjusted for baseline covariates.ResultsBaseline samples were available from 751 patients. According to our prespecified analysis plan, IL6 was predictive of a therapeutic advantage with bevacizumab for PFS (P = 0.007) and OS (P = 0.003). IL6 and OPN were found to be negative prognostic markers for both PFS and OS (P < 0.001). Patients with high median IL6 levels (dichotomized at the median) treated with bevacizumab had longer PFS (14.2 vs. 8.7 months) and OS (39.6 vs. 33.1 months) compared with placebo.ConclusionsThe inflammatory cytokine IL6 may be predictive of therapeutic benefit from bevacizumab when combined with carboplatin and paclitaxel. Aligning with results observed in patients with renal cancer treated with antiangiogenic therapies, it appears plasma IL6 may also define those patients with EOC more or less likely to benefit from the addition of bevacizumab to standard chemotherapy.

Published
2020

11. Lost, mislabeled, and mishandled surgical and clinical pathology specimens: A systematic review of published literature.

Author

Carmack, Heather J, Lazenby, Braidyn S, Wilson, Kylie J, Bakkum-Gamez, Jamie N, and Carranza, Leslie

Subjects
CLINICAL pathology, SURGICAL pathology, PATIENT safety, OPERATIVE surgery, PATHOLOGY
Abstract

Objectives To perform a systematic review of published academic literature related to lost, mislabeled, and mishandled surgical and clinical pathology specimens during the preanalytical stage. Methods The authors used Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines to search PubMed, MEDLINE, Web of Science, and Scopus for relevant articles published from January 1, 1990, to May 1, 2023. Results The authors screened 1313 articles and identified 44 peer-reviewed, English-language articles published between 1990 and 2021 for inclusion in the final systematic review. Most articles (n = 36) reported results from US-based facilities. Articles primarily focused on general clinical and general surgical pathology. Analysis of the articles revealed that articles reported a range of methodological approaches, including incident reports, implementation analyses, case studies, and commentary recommendations. Most articles focused on mislabeling errors (61.3%) and missing or lost specimens (18.2%), while several articles combined specimen errors (20.5%). Several implementation studies (22.7%) reported using multiple interventions to mitigate errors. Implementation efforts reported between 70% and 100% reduction in pathology errors. Conclusions The review highlights the limited research on the topic, with an average of 2 articles per year discussing lost, mislabeled, or mishandled specimens. Intervention studies addressed The Joint Commission's patient safety goals for laboratory practice. More research is needed about error incidents and reporting in non-Western countries to gain a more global perspective on the topic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability

Author

Torres, Diogo, Wang, Chen, Kumar, Amanika, Bakkum-Gamez, Jamie N, Weaver, Amy L, McGree, Michaela E, Konecny, Gottfried E, Goode, Ellen L, and Cliby, William A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Ovarian Cancer, Cancer, Clinical Research, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Cystadenocarcinoma, Serous, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Proportional Hazards Models, Survival Rate, High-grade serous ovarian cancer, Epithelial ovarian cancer, Mesenchymal, Residual disease, TCGA subtype, Molecular subtype, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveTo investigate the relationship between molecular subtype, intraperitoneal (IP) disease dissemination patterns, resectability, and overall survival (OS) in advanced high-grade serous ovarian cancer (HGSOC).MethodsPatients undergoing primary surgery for stage III-IV HGSOC at Mayo Clinic from 1994 to 2011 were categorized into three IP disease dissemination patterns: upper abdominal or miliary; lower abdominal; and pelvic. Residual disease was defined as 0 (RD0), 0.1-0.5, 0.6-1.0, or >1 cm. Molecular subtypes were derived from Agilent 4x44k tumor mRNA expression profiles and categorized as mesenchymal (MES) or non-mesenchymal (non-MES).ResultsOperative and molecular data was available for 334 patients. Median OS was shorter in patients with MES compared to non-MES subtypes (34.2 vs 44.6 months; P = 0.009). Patients with MES subtype were more likely to have upper abdominal/miliary disease compared to non-MES subtype (90% vs. 72%, P

Published
2018

13. Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer

Author

Torres, Diogo, Kumar, Amanika, Wallace, Sumer K, Bakkum-Gamez, Jamie N, Konecny, Gottfried E, Weaver, Amy L, McGree, Michaela E, Goode, Ellen L, Cliby, William A, and Wang, Chen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Ovarian Cancer, Rare Diseases, Clinical Research, Cancer, Good Health and Well Being, Aged, Cystadenocarcinoma, Serous, Female, Humans, Middle Aged, Neoplasm Staging, Neoplasm, Residual, Ovarian Neoplasms, Peritoneal Cavity, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveTo investigate the association between intraperitoneal (IP) disease dissemination patterns, residual disease (RD), surgical complexity, and molecular subtypes in advanced high-grade serous ovarian cancer (HGSOC).Methods741 patients with operable stage III-IV HGSOC undergoing primary debulking surgery at Mayo Clinic from 1994 to 2011 were categorized into four mutually exclusive IP disease dissemination patterns: upper abdominal (60%), miliary (16%), lower abdominal (15%), and pelvic (9%). Surgical complexity was classified as high, intermediate, or low; RD status was defined as 0, 0.1-0.5, 0.6-1.0, or >1cm; molecular subtype assignments were derived from expression profiling of tumors from 334 patients.ResultsPatients with either miliary or upper abdominal dissemination patterns were less likely to achieve RD0 compared to patients with pelvic and lower abdominal dissemination patterns (25% vs. 9% and 62%, each P

Published
2017

16. Contributors

Author

Achtari, Chahin, primary, Altman, Alon D., additional, Bakkum-Gamez, Jamie N., additional, Bennett, Victoria, additional, Bhandoria (Prakash), Geetu, additional, Bisch, Steven, additional, de Boer, Hans D., additional, Bollag, Laurent, additional, Cope, Adela, additional, Elias, Kevin M., additional, Fawcett, William John, additional, Fay, Emily, additional, Glaser, Gretchen E., additional, Huepenbecker, Sarah P., additional, Iniesta, Maria D., additional, Jones, Chris, additional, Kalogera, Eleftheria, additional, Kelliher, Leigh, additional, Khan, Zaraq, additional, Korteweg, Fleurisca J., additional, Kumar, Amanika, additional, Lovely, Jenna K., additional, Meyer, Larissa A., additional, Miralpeix, Ester, additional, Pache, Basile, additional, Robert, Magali, additional, Scott, Michael J., additional, Shah, Pranav, additional, Shylasree, T.S., additional, Smid-Nanninga, Henriette, additional, Soto, Diana Encalada, additional, Sultan, Pervez, additional, Swenson, Carolyn, additional, Taylor, Jolyn S., additional, Trudeau, Pat, additional, Wagenaar, Leense S., additional, Wallace, Sumer K., additional, Warring, Simrit K., additional, and Wijk, Lena, additional

Published
2022
Full Text
View/download PDF

19. List of contributors

Author

Advincula, Arnold P., primary, Bakkum-Gamez, Jamie N., additional, Bouchard-Fortier, Genevieve, additional, Burke, Anne, additional, Clark, Leslie H., additional, Coleman, Robert L., additional, Covens, Allan, additional, Cowley, Deborah S., additional, Davis, Anne R., additional, Dolan, Mary Segars, additional, Dotters-Katz, Sarah K., additional, Douglas, Nataki C., additional, Dowdy, Sean C., additional, Eckert, Linda O., additional, Fialkow, Michael, additional, Forman, Eric J., additional, Frumovitz, Michael, additional, Gehrig, Paola Alvarez, additional, Gershenson, David M., additional, Gilner, Jennifer Bushman, additional, Havrilesky, Laura J., additional, Hill, Cherie C., additional, Hur, Hye-Chun, additional, Jhingran, Anuja, additional, Kelley, James M., additional, Kirby, Anna C., additional, Kuller, Jeffrey A., additional, Lara-Torre, Eduardo, additional, Lentz, Gretchen M., additional, Lobo, Roger A., additional, Lu, Karen H., additional, Mendiratta, Vicki, additional, Meyer, Larissa A., additional, Miller, Jane L., additional, Nica, Andra, additional, Nunziato, Jaclyn D., additional, Orr, James W., additional, Padro, Amanda, additional, Phoolcharoen, Natacha, additional, Price, Thomas M., additional, Rackow, Beth W., additional, Ramirez, Pedro T., additional, Raymond, Licia, additional, Rhee, Eleanor H.J., additional, Rivlin, Katherine, additional, Rock, David T., additional, Ryntz, Timothy, additional, Salcedo, Mila Pontremoli, additional, Salvo, Gloria, additional, Sandadi, Samith, additional, Schmeler, Kathleen M., additional, Smith, Judith A., additional, Soliman, Pamela T., additional, Sood, Anil K., additional, Thaker, Premal H., additional, Truong, Mireille, additional, Turocy, Jenna, additional, Valea, Fidel A., additional, Watson, Catherine H., additional, Westin, Shannon N., additional, and Williams, Zev, additional

Published
2022
Full Text
View/download PDF

21. When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic

Author

Fader, Amanda N., Huh, Warner K., Kesterson, Joshua, Pothuri, Bhavana, Wethington, Stephanie, Wright, Jason D., Bakkum-Gamez, Jamie N., Soliman, Pamela T., Sinno, Abdulrahman K., Leitao, Mario, Martino, Martin A., Karam, Amer, Rossi, Emma, Brown, Jubilee, Blank, Stephanie, Burke, William, Goff, Barbara, Yamada, S. Diane, Uppal, Shitanshu, and Dowdy, Sean C.

Published
2020
Full Text
View/download PDF

29. Erratum to: Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer

Author

Roy, Debarshi, Mondal, Susmita, Wang, Chen, He, Xiaoping, Khurana, Ashwani, Giri, Shailendra, Hoffmann, Robert, Jung, Deok-Beom, Kim, Sung H, Chini, Eduardo N, Periera, Juliana Camacho, Folmes, Clifford D, Mariani, Andrea, Dowdy, Sean C, Bakkum-Gamez, Jamie N, Riska, Shaun M, Oberg, Ann L, Karoly, Edward D, Bell, Lauren N, Chien, Jeremy, and Shridhar, Viji

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Good Health and Well Being, Medical biochemistry and metabolomics, Oncology and carcinogenesis
Abstract

[This corrects the article DOI: 10.1186/2049-3002-2-13.].

Published
2014

30. Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer

Author

Roy, Debarshi, Mondal, Susmita, Wang, Chen, He, Xiaoping, Khurana, Ashwani, Giri, Shailendra, Hoffmann, Robert, Jung, Deok-Beom, Kim, Sung H, Chini, Eduardo N, Periera, Juliana Camacho, Folmes, Clifford D, Mariani, Andrea, Dowdy, Sean C, Bakkum-Gamez, Jamie N, Riska, Shaun M, Oberg, Ann L, Karoly, Edward D, Bell, Lauren N, Chien, Jeremy, and Shridhar, Viji

Subjects
Medical Biochemistry and Metabolomics, Biomedical and Clinical Sciences, Rare Diseases, Ovarian Cancer, Biotechnology, Cancer, Genetics, Aetiology, 2.1 Biological and endogenous factors, HSulf-1, Lipogenesis, Lipolysis, Lipid droplets, Microarray and metabolite profiling, Medical biochemistry and metabolomics, Oncology and carcinogenesis
Abstract

BackgroundLoss of the endosulfatase HSulf-1 is common in ovarian cancer, upregulates heparin binding growth factor signaling and potentiates tumorigenesis and angiogenesis. However, metabolic differences between isogenic cells with and without HSulf-1 have not been characterized upon HSulf-1 suppression in vitro. Since growth factor signaling is closely tied to metabolic alterations, we determined the extent to which HSulf-1 loss affects cancer cell metabolism.ResultsIngenuity pathway analysis of gene expression in HSulf-1 shRNA-silenced cells (Sh1 and Sh2 cells) compared to non-targeted control shRNA cells (NTC cells) and subsequent Kyoto Encyclopedia of Genes and Genomics (KEGG) database analysis showed altered metabolic pathways with changes in the lipid metabolism as one of the major pathways altered inSh1 and 2 cells. Untargeted global metabolomic profiling in these isogenic cell lines identified approximately 338 metabolites using GC/MS and LC/MS/MS platforms. Knockdown of HSulf-1 in OV202 cells induced significant changes in 156 metabolites associated with several metabolic pathways including amino acid, lipids, and nucleotides. Loss of HSulf-1 promoted overall fatty acid synthesis leading to enhance the metabolite levels of long chain, branched, and essential fatty acids along with sphingolipids. Furthermore, HSulf-1 loss induced the expression of lipogenic genes including FASN, SREBF1, PPARγ, and PLA2G3 stimulated lipid droplet accumulation. Conversely, re-expression of HSulf-1 in Sh1 cells reduced the lipid droplet formation. Additionally, HSulf-1 also enhanced CPT1A and fatty acid oxidation and augmented the protein expression of key lipolytic enzymes such as MAGL, DAGLA, HSL, and ASCL1. Overall, these findings suggest that loss of HSulf-1 by concomitantly enhancing fatty acid synthesis and oxidation confers a lipogenic phenotype leading to the metabolic alterations associated with the progression of ovarian cancer.ConclusionsTaken together, these findings demonstrate that loss of HSulf-1 potentially contributes to the metabolic alterations associated with the progression of ovarian pathogenesis, specifically impacting the lipogenic phenotype of ovarian cancer cells that can be therapeutically targeted.

Published
2014

37. Supplemental Figure 1 from Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers

Author

Bramblet, Rachel M., primary, Bakkum-Gamez, Jamie N., primary, Slettedahl, Seth W., primary, Foote, Patrick H., primary, Taylor, William R., primary, Berger, Calise K., primary, Gysbers, Brianna J., primary, Arndt, Jacquelyn, primary, Chen, Longwen, primary, Doering, Karen A., primary, Burger, Kelli N., primary, Mahoney, Douglas W., primary, Sherman, Mark E., primary, Kisiel, John B., primary, and Samadder, N. Jewel, primary

Published
2023
Full Text
View/download PDF

38. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial

Author

Swisher, Elizabeth M., primary, Rayes, Nadine, additional, Bowen, Deborah, additional, Peterson, Christine B., additional, Norquist, Barbara M., additional, Coffin, Tara, additional, Gavin, Kathleen, additional, Polinsky, Deborah, additional, Crase, Jamie, additional, Bakkum-Gamez, Jamie N., additional, Blank, Stephanie V., additional, Munsell, Mark F., additional, Nebgen, Denise, additional, Fleming, Gini F., additional, Olopade, Olufunmilayo I., additional, Law, Sherman, additional, Zhou, Alicia, additional, Levine, Douglas A., additional, D’Andrea, Alan, additional, and Lu, Karen H., additional

Published
2023
Full Text
View/download PDF

39. Data from Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers

Author

Bramblet, Rachel M., primary, Bakkum-Gamez, Jamie N., primary, Slettedahl, Seth W., primary, Foote, Patrick H., primary, Taylor, William R., primary, Berger, Calise K., primary, Gysbers, Brianna J., primary, Arndt, Jacquelyn, primary, Chen, Longwen, primary, Doering, Karen A., primary, Burger, Kelli N., primary, Mahoney, Douglas W., primary, Sherman, Mark E., primary, Kisiel, John B., primary, and Samadder, N. Jewel, primary

Published
2023
Full Text
View/download PDF

40. Supplemental Figure 2 from Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers

Author

Bramblet, Rachel M., primary, Bakkum-Gamez, Jamie N., primary, Slettedahl, Seth W., primary, Foote, Patrick H., primary, Taylor, William R., primary, Berger, Calise K., primary, Gysbers, Brianna J., primary, Arndt, Jacquelyn, primary, Chen, Longwen, primary, Doering, Karen A., primary, Burger, Kelli N., primary, Mahoney, Douglas W., primary, Sherman, Mark E., primary, Kisiel, John B., primary, and Samadder, N. Jewel, primary

Published
2023
Full Text
View/download PDF

41. Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers

Author

Bramblet, Rachel M., primary, Bakkum-Gamez, Jamie N., additional, Slettedahl, Seth W., additional, Foote, Patrick H., additional, Taylor, William R., additional, Berger, Calise K., additional, Gysbers, Brianna J., additional, Arndt, Jacquelyn, additional, Chen, Longwen, additional, Doering, Karen A., additional, Burger, Kelli N., additional, Mahoney, Douglas W., additional, Sherman, Mark E., additional, Kisiel, John B., additional, and Samadder, N. Jewel, additional

Published
2023
Full Text
View/download PDF

45. Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease

Author

Ducie, Jennifer A., Eriksson, Ane Gerda Zahl, Ali, Narisha, McGree, Michaela E., Weaver, Amy L., Bogani, Giorgio, Cliby, William A., Dowdy, Sean C., Bakkum-Gamez, Jamie N., Soslow, Robert A., Keeney, Gary L., Abu-Rustum, Nadeem R., Mariani, Andrea, and Leitao, Mario M., Jr

Published
2017
Full Text
View/download PDF

47. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction

Author

Ray, Upasana, primary, Thirusangu, Prabhu, additional, Jin, Ling, additional, Xiao, Yinan, additional, Pathoulas, Christopher L., additional, Staub, Julie, additional, Erskine, Courtney L., additional, Dredge, Keith, additional, Hammond, Edward, additional, Block, Matthew S., additional, Kaufmann, Scott H., additional, Bakkum-Gamez, Jamie N., additional, and Shridhar, Viji, additional

Published
2023
Full Text
View/download PDF

50. In Reply

Author

Gebhart, John B., Schmitt, Jennifer J., Baker, Mary V., Occhino, John A., McGree, Michaela E., Weaver, Amy L., Bakkum-Gamez, Jamie N., Dowdy, Sean C., and Pasupathy, Kalyan S.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results